Moreover, given no heterogeneous treatment effects found by age, gender, or diabetes severity for GLP-1RAs versus insulin in our previous analyses [6] and limited study subjects with different patient characteristics in the present study, performing the cost-effectiveness analysis stratified by different patient demographic or clinical characteristics would be infeasible. The gene discussed is INS; the disease is diabetes mellitus.